Clinics, Labs and Data: How to Evaluate an Evidenced Healthcare Roll-Up
Completed acquisitions provide a basis for evaluating integration. Ownership, clinical workflow, data permissions and outcomes still require separate proof.
LongevityNext Intelligence
Deals & Capital
Funding, acquisitions, and the businesses being built around longevity.
Women’s Midlife Care: Where Capital Is Going—and What Clinical Evidence Supports
Dated care and product transactions reveal distinct business models. Symptom treatment, service performance and longevity claims require different evidence.
NewLimit’s Series C: What Disclosed Capital and Company Milestones Actually Show
What NewLimit’s disclosed Series C and development updates show about company building, without inferring valuation, investor motives or clinical success.
Diagnostics, Canine Therapeutics and Drug Discovery: Three Different Business Risks
Diagnostics, canine therapeutics and human-drug discovery face different operating and regulatory tests. Dated examples clarify the distinctions.
Longevity Capital in 2026: Disclosed Deals, Different Instruments, and the Limits of the Evidence
Nine disclosed 2026 transactions show different instruments and business models—not a measure of total longevity investment or clinical validation.